-
Cancer research in the UK faces ‘perfect storm’ of funding cuts
pharmatimes
April 01, 2021
The Institute of Cancer Research, London (ICR) has made an appeal to Prime Minister Boris Johnson after identifying a ‘perfect storm’ of funding cuts that could impact cancer research in the UK.
-
NHS extends ‘COVID-friendly’ at-home cancer care
pharmatimes
March 31, 2021
The NHS has announced that thousands of people will benefit from the extension of ‘COVID-friendly’ cancer treatments which can be taken at home.
-
Machine learning used to predict most effective cancer drugs
europeanpharmaceuticalreview
March 29, 2021
According to a new study, Drug Ranking Using Machine Learning (DRUML) can accurately rank cancer therapies by efficacy across a range of cancer types.
-
University team uses AI to decode asbestos-linked cancer
pharmaceutical-technology
March 29, 2021
Researchers at the University of Leicester have used artificial intelligence (AI) to gain new insights into mesothelioma, a cancer caused by breathing asbestos particles that typically occurs in the linings of the lungs or abdomen.
-
Biobohemia Released Paper on the Discovery of the Antigenic Essence of Cancer Cells
prnasia
March 17, 2021
Scientists announced today that they have discovered why they have not succeeded in developing a vaccine against cancer. Vaccination is a powerful tool that has helped us cope with many dangerous diseases, and it is an effective means of combatting ...
-
New Data Demonstrates Nu.Q® is Effective in Monitoring Treatment of Sepsis
prnasia
March 17, 2021
VolitionRx Limited, a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, has been working with Swiss-based Santersus AG, a ...
-
CRISPR therapies could be one of the most transformative in human history, says GlobalData
europeanpharmaceuticalreview
March 17, 2021
Adam Pearson, Senior Oncology Analyst at GlobalData, comments on the development of CRISPR-based therapies and outlines potential opportunities and challenges in the space.
-
Caris Life Sciences Study Provides First Systematic Assessment of RNA Expression of Key Molecules Involved in the Infectious Process Leading to COVID-19 in Advanced Cancer
prnewswire
March 17, 2021
Patients with cancer demonstrate particularly poor outcomes from COVID-19. Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, has published results from a ...
-
Immutep Secures Second Patent Grant for Eftilagimod Alpha, A Pd-1 Pathway Inhibitor Combination
americanpharmaceuticalreview
March 16, 2021
Immutep has announced the grant of patent number 10,940,181 entitled “Combined Preparations for the Treatment of Cancer or Infection” by the United States Patent & Trade Mark Office (USPTO).
-
CRISPR-based cancer therapies likely to be a disruptive technology in healthcare: GlobalData
expresspharma
March 15, 2021
Three leading companies racing to bring CRISPR therapies to the clinic are CRISPR Therapeutics, Intellia Therapeutics and Editas Medicine.